ArticleMolecular pharmaceutics2024

Engineering and Characterization of a Long-Half-Life Relaxin Receptor RXFP1 Agonist.

Sarah C Erlandson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.